Your browser is no longer supported. Please, upgrade your browser.
ICON Public Limited Company
Index- P/E40.65 EPS (ttm)6.83 Insider Own4.00% Shs Outstand52.91M Perf Week4.85%
Market Cap22.10B Forward P/E25.07 EPS next Y11.07 Insider Trans0.00% Shs Float51.71M Perf Month3.29%
Income363.90M PEG3.56 EPS next Q2.42 Inst Own81.50% Short Float1.63% Perf Quarter29.67%
Sales3.19B P/S6.92 EPS this Y-9.40% Inst Trans1.10% Short Ratio1.45 Perf Half Y31.68%
Book/sh38.33 P/B7.24 EPS next Y20.86% ROA10.70% Target Price249.23 Perf Year36.07%
Cash/sh13.28 P/C20.90 EPS next 5Y11.43% ROE19.30% 52W Range168.76 - 301.72 Perf YTD42.36%
Dividend- P/FCF44.53 EPS past 5Y9.40% ROI15.60% 52W High-8.00% Beta0.83
Dividend %- Quick Ratio2.10 Sales past 5Y12.20% Gross Margin28.40% 52W Low64.48% ATR6.89
Employees16480 Current Ratio2.10 Sales Q/Q40.50% Oper. Margin14.30% RSI (14)65.99 Volatility1.79% 2.78%
OptionableYes Debt/Eq0.00 EPS Q/Q53.60% Profit Margin11.40% Rel Volume0.77 Prev Close276.57
ShortableYes LT Debt/Eq0.17 EarningsJul 21 AMC Payout0.00% Avg Volume580.13K Price277.58
Recom2.10 SMA203.20% SMA507.03% SMA20025.04% Volume451,840 Change0.37%
Sep-27-21Upgrade JP Morgan Neutral → Overweight $230 → $320
Aug-05-21Resumed Credit Suisse Outperform $250
Jul-23-21Upgrade Citigroup Neutral → Buy $260
Jul-14-21Initiated Citigroup Neutral $220
Apr-13-21Resumed BofA Securities Neutral $220
Apr-01-21Upgrade Wells Fargo Equal Weight → Overweight $200 → $235
Mar-08-21Upgrade Robert W. Baird Neutral → Outperform $215
Mar-03-21Initiated Barclays Equal Weight $200
Mar-01-21Upgrade UBS Neutral → Buy $207 → $232
Feb-26-21Upgrade Truist Hold → Buy $280
Jul-24-20Downgrade BofA Securities Buy → Neutral
Apr-20-20Downgrade Robert W. Baird Outperform → Neutral $151
Mar-26-20Upgrade Barclays Equal Weight → Overweight
Mar-02-20Initiated Deutsche Bank Hold
Jan-27-20Downgrade SunTrust Buy → Hold $170 → $182
Jan-08-20Initiated Wells Fargo Equal Weight $180
Jan-07-20Initiated Citigroup Neutral $185
Sep-23-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jul-26-19Upgrade UBS Sell → Neutral
Jan-25-19Upgrade Mizuho Neutral → Buy
Oct-15-21 08:36AM  
Oct-13-21 03:01PM  
Oct-12-21 07:55PM  
Sep-22-21 04:05PM  
Sep-19-21 10:24AM  
Sep-02-21 06:00AM  
Aug-19-21 09:27AM  
Aug-18-21 02:24PM  
Aug-04-21 05:38AM  
Jul-30-21 09:15AM  
Jul-29-21 12:20PM  
Jul-26-21 09:27AM  
Jul-22-21 06:01PM  
Jul-21-21 05:35PM  
Jul-19-21 12:45PM  
Jul-14-21 03:00PM  
Jul-09-21 02:35AM  
Jul-06-21 11:37AM  
Jul-02-21 12:45PM  
Jul-01-21 08:43AM  
Jun-28-21 06:07PM  
Jun-17-21 09:25AM  
Jun-15-21 04:15PM  
Jun-14-21 07:59AM  
May-28-21 04:08AM  
May-25-21 06:00AM  
May-05-21 06:30AM  
Apr-30-21 06:31PM  
Apr-28-21 05:55PM  
Apr-20-21 04:35AM  
Apr-16-21 06:58AM  
Apr-14-21 01:04PM  
Mar-15-21 02:49AM  
Mar-09-21 10:00AM  
Mar-08-21 06:44AM  
Mar-01-21 11:02PM  
Feb-26-21 03:26PM  
Feb-25-21 02:30PM  
Feb-24-21 02:44PM  
Feb-23-21 10:16AM  
Feb-16-21 07:30AM  
Feb-13-21 03:45AM  
Feb-10-21 12:31PM  
Feb-08-21 04:30AM  
Feb-04-21 12:10PM  
Jan-14-21 01:17AM  
Jan-07-21 04:15PM  
Jan-04-21 04:15AM  
Dec-15-20 01:22AM  
Nov-11-20 06:00AM  
Oct-30-20 07:00AM  
Oct-24-20 09:42AM  
Oct-22-20 08:01PM  
Oct-21-20 05:35PM  
Oct-19-20 09:00AM  
Oct-07-20 05:00AM  
Sep-29-20 08:56AM  
Sep-25-20 11:07AM  
Sep-03-20 04:30AM  
Sep-02-20 07:00AM  
Aug-26-20 12:50PM  
Aug-21-20 04:30AM  
Jul-30-20 01:30PM  
Jul-27-20 08:29PM  
Jul-23-20 09:01PM  
Jul-22-20 07:35PM  
Jun-18-20 03:33PM  
Jun-11-20 08:05AM  
May-27-20 06:00AM  
May-26-20 11:40AM  
May-21-20 11:46AM  
May-13-20 06:00AM  
May-05-20 04:30AM  
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.